Combination of inhibitors for two glycolytic enzymes portrays high synergistic efficacy against Cryptosporidium parvum

Immunology and Microbiology

• Infectious Disease 100%
• Cryptosporidium parvum 100%
• Energy Yield 100%
• Infection 100%
• In Vitro 100%
• Lactic Acid 100%
• Lactate 100%
• Parasite 100%
• Mouse Model 50%
• Citric Acid Cycle 50%
• Prevalence 50%
• Apicomplexa 50%
• Cryptosporidium 50%
• Protozoa 50%
• Oxidative Phosphorylation 50%
• Immunocompromised Patient 50%
• Susceptible Population 50%
• Population Risk 50%
• Kinase 50%
• Phosphotransferase 50%
• Glycolysis 50%

Keyphrases

• Cryptosporidium Parvum 100%
• Glycolytic Enzymes 100%
• Synergistic Efficacy 100%
• C. Parvum 100%
• Cryptosporidiosis 75%
• Energy Production 50%
• Enhanced Efficacy 50%
• Immunodeficient Mice 50%
• Metabolizable Energy 50%
• Bacterial Type 50%
• Compound Combinations 50%
• Tricarboxylic Acid Cycle (TCA cycle) 25%
• Synergistic Effect 25%
• High Prevalence 25%
• Mouse Model 25%
• Effective Treatment 25%
• Glycolysis 25%
• Therapeutic Agents 25%
• Life-threatening 25%
• Treat-all 25%
• Oxidative Phosphorylation (OXPHOS) 25%
• Lactate Dehydrogenase 25%
• Apicomplexan 25%
• Pyruvate Kinase 25%
• Enteric Infections 25%
• Protozoan Parasites 25%
• Cryptosporidium 25%
• Neonatal Calves 25%
• Immunocompromised Patients 25%
• Susceptible Population 25%
• Intestinal Lesions 25%
• Catalytic Steps 25%
• Total Effective Dose 25%
• Lactate Dehydrogenase Inhibitors 25%
• At-risk Populations 25%
• Anticryptosporidial 25%

Biochemistry, Genetics and Molecular Biology

• Enzyme 100%
• Lactate Dehydrogenase 100%
• Energy Yield 100%
• Cryptosporidium parvum 100%
• Parasite 100%
• Citric Acid Cycle 50%
• Oxidative Phosphorylation 50%
• Mouse Model 50%
• Prevalence 50%
• Pyruvate Kinase 50%
• Susceptible Population 50%
• Apicomplexa 50%
• Population Risk 50%
• Cryptosporidium 50%
• Glycolysis 50%
• Protozoan 50%